Literature DB >> 1627862

Gadolinium-enhanced high-resolution MR angiography with adaptive vessel tracking: preliminary results in the intracranial circulation.

W Lin1, E M Haacke, A S Smith, M E Clampitt.   

Abstract

To overcome problems associated with poor contrast between vessels and background tissue in time-of-flight magnetic resonance angiography, the role of intravenous gadopentetate dimeglumine in conjunction with a postprocessing adaptive vessel tracking scheme was studied. Vessel tracking makes it possible to discriminate arteries from veins, to prevent problems associated with other bright tissues on maximum-intensity projections, and to increase the signal-to-noise ratio. Short, asymmetric, velocity-compensated field echoes were used in conjunction with high-resolution imaging techniques to spatially discriminate between adjacent vessels and stationary background tissue. Gadopentetate dimeglumine was shown to be useful for visualization of small vessels, aneurysms, and regions of slow flow, when used with this post-processing scheme.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1627862     DOI: 10.1002/jmri.1880020305

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  3 in total

1.  Improved quality and diagnostic confidence achieved by use of dose-reduced gadolinium blood-pool agents for time-resolved intracranial MR angiography.

Authors:  S Dehkharghani; J Kang; A M Saindane
Journal:  AJNR Am J Neuroradiol       Date:  2013-08-22       Impact factor: 3.825

2.  The optimization of scan timing for contrast-enhanced magnetic resonance angiography.

Authors:  J J Lee; P J Tirman; Y Chang; H K Ryeom; S K Lee; Y S Kim; D S Kang
Journal:  Korean J Radiol       Date:  2000 Jul-Sep       Impact factor: 3.500

3.  Differential effects of two MRI contrast agents on the integrity and distribution of rAAV2 and rAAV5 in the rat striatum.

Authors:  Sue Osting; Antonette Bennett; Shelby Power; Jordan Wackett; Samuel A Hurley; Andrew L Alexander; Mavis Agbandje-Mckena; Corinna Burger
Journal:  Mol Ther Methods Clin Dev       Date:  2014-01-08       Impact factor: 6.698

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.